Mesalamine for inflammatory bowel disease: Recent reappraisals

Inflammation and Allergy - Drug Targets

Volumn 7, Issue 1, 2008, Pages 1-5

  Actis, Giovanni C ^a   Pazienza, Paola ^a   Rosina, Floriano ^a  

^a GRADENIGO HOSPITAL   (Italy)

Author keywords

Colorectal cancer; Inflammatory bowel disease; Mesalamine; Reappraisal

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 ACETAMIDOSALICYLIC ACID; 6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; BALSALAZIDE; CYCLOSPORIN; DRUG METABOLITE; MERCAPTOPURINE; MESALAZINE; OLSALAZINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SALAZOSULFAPYRIDINE; STEROID; TIOGUANINE; TROGLITAZONE;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; BRONCHIOLITIS OBLITERANS; CANCER INHIBITION; CANCER RISK; CLINICAL TRIAL; COLON RESECTION; COLORECTAL CANCER; CROHN DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG USE; DRUG WITHDRAWAL; ENTERITIS; HEPATITIS; HUMAN; IN VIVO STUDY; INFECTION; INTERSTITIAL NEPHRITIS; LEUKOPENIA; LOEFFLER PNEUMONIA; LUNG TOXICITY; MALIGNANT TRANSFORMATION; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREATITIS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PLEURA EFFUSION; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REMISSION; RESPIRATORY FAILURE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; ULCERATIVE COLITIS;

EID: 43449110754     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152808784165180     Document Type: Article

References (29)

1. Bouma, G.; Strober, W. Nat. Rev. Immunol., 2003, 3, 521.
2. Loftus, C.G.; Loftus, E.V. Jr.; Harmsen, W.S.; Zinsmeister, A.R.; Tremaine, W.J.; Melton, L.J.3rd.; Sandborn, W.J. Inflamm. Bowel Dis., 2007, 13, 254.
3. Hanauer, S.B. Best Pract. Res. Clin. Gastroenterol., 2003, 17, 131.
4. Frieri, G.; Giacomelli, R.; Pimpo, M.; Palumbo, G.; Passacantando, A.; Pantaloni, G.; Caprilli, R. GUT, 2000, 47, 410.
5. Klotz, U.; Schwab, M. Adv. Drug Deliv. Rev., 2005, 57, 267.
6. Vree, T.B.; Dammers, E.; Exler, P.S.; Sorgel, F.; Bondesen, S.; Maes, R.A. Int. J. Clin. Pharmacol. Ther., 2000, 38, 514.
7. van Bodegraven, A.A.; Mulder, C.J. World J. Gastroenterol., 2006, 12, 6115.
8. Ransford, R.A.J.; Langman, M.J.S. GUT, 2002, 51, 536.
9. Gisbert, J.P.; Gonzalez-Lama, Y.; Mate, J. Inflamm. Bowel Dis., 2007, 13, 629.
10. Storch, I.; Sachar, D.B.; Katz, S. Inflamm. Bowel Dis., 2003, 9,104.
11. Actis, G.C.; Ottobrelli, A.; Baldi, S.; Scappaticci, E.; Modena, V.; Fusaro, E.; Mengozzi, G.; Rizzetto, M. Mt. Sinai. J. Med., 2005, 72, 136.
12. Hanauer, S.B.; Schwartz, J.; Robinson, M.; Roufail, W.; Arora, S.; Cello, J.; Safdi, M.; and the Pentasa® study group. Am. J. Gastroenterol., 1993, 88, 1188.
13. Sutherland, L.; Macdonald, J.K. Cochrane Database Syst. Rev., 2006 [2]: CD000544.
14. Kane, S.; Huo, D.; Aikens, J.; Hanauer, S.B. Am. J. Med., 2003, 114, 39.
15. Rutter, M.; Saunders, B.; Wilkinson, K.; Rumbles, S.; Schofield, G.; Kamm, M.; Williams, C.; Price, A.; Talbot, I.; Forbes, A. Gastroenterology, 2004, 126, 451.
16. Desreumaux, P.; Ghosh, S. Aliment. Pharmacol. Ther., 2006, 24, 2.
17. Yang C.; Desreumaux P. World J. Gastroenterol., 2005, 11, 309.
18. E. Aubrey Thompson. Mol. Cells, 2007, 24, 167.
19. Dubuquoy, L.; Rousseaux, C.; Thuru, X.; Peyrin-Biroulet, L.; Romano, O.; Chavatte, P.; Chamaillard, M.; Desreumaux, P. GUT, 2006, 55, 1341.
20. Present, D.H.; Korelitz, B.I.; Wisch, N.; Glass, J.L.; Sachar, D.B.; Pasternack, B.S. N. Engl. J. Med., 1980, 302, 981.
21. Actis, G.C.; Fadda, M.; David E.; Sapino, A. BMC Gastroenterology, 2007, 7, 13.
22. Blumenstein, I.; Bock, H.; Weber, C.; Rambow, A.; Tacke, W.; Kihn, R.; Pfaff, R.; Orlemann, S.; Schaeffer, R.; Schroeder, O.; Dignass, A.; Hartmann, F.; Stein, J. Inflamm. Bowel Dis., 2008, 14, 53.
23. Siegel, C.A.; Sands, B.E. Aliment. Pharmacol. Ther., 2005, 22, 1.
24. Winter, J.; Walker, A.; Shapiro, D.; Gaffney, D.; Spooner, R.J.; Mills, P.R. Aliment. Pharmacol. Ther., 2004, 20, 593.
25. Dewit, O.; Vanheuverzwyn, R.; Desager, J.P.; Horsmans, Y. Aliment. Pharmacol. Ther., 2002, 16, 79.
26. Hande, S.; Wilson-Rich, N.; Bousvaros, A.; Zholudev, A.; Maurer, R.; Banks, P.; Makrauer, F.; Reddy, S.; Burakoff, R.; Friedman, S. Inflamm. Bowel Dis., 2006, 12, 251.
27. de Boer, N.K.; Wong, D.R.; Jharap, B.; de Graaf, P.; Hooymans, P.M.; Mulder, C.J.; Rijmen, F.; Engels, L.G.; van Bodegraven, A.A. Am. J. Gastroenterol., 2007, 102, 2747.
28. Sandborn, W.J.; Kamm, M.A.; Lichtenstein, G.R.; Lyne, A.; Butler, T.; Joseph, R.E. Aliment. Pharmacol. Ther., 2007, 26, 205.
29. Actis, G.C.; Marzano, A.; Pellicano, R.; Rizzetto, M. Inflamm. How important is mesalamine in the maintenance of steroid-refractory colitis? Inflammatory Bowel Diseases., 14(7) pp-1026 2008; DOI: 10.1002/ibd.20422.